Stocks-VRDN-Viridian Therapeutics Inc

VRDN Viridian Therapeutics Inc

0 0 (0%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Trade

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2022: Viridian Therapeutics Inc's revenues decreased by 40.20% and amounted to 1.77M. Net income decreased by 63.54% to -129.87M. Net assets decreased by NaN to 395.06M and EPS increased from -6.66 to -4.05.
VRDN's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
N/A
Net Profit Margin
-5,373.08%
Operating Margin
-66,869.74%
Return On Investment
-93.83%